Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced its participation in various upcoming industry conferences.
The Company will be presenting updated clinical data from the Phase I TACTI-mel trial in metastatic melanoma for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) and new data relating to its pre-clinical product candidate, IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases, at industry conferences in March 2019.
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells.
Immutep generates no net income so this trade set up is strictly based on price pattern.
The current Annual EPS Growth for Immutep Ltd ADR is 0.00 which is less than the 30% average found is strong trending, fundamentally sound companies.
The current Quarterly EPS Growth for Immutep Ltd ADR is 0.00 which is less than the 25% average found is strong trending stocks even during or before huge price moves.
The current Quarterly Sales Growth for Immutep Ltd ADR is 0.00 which is less than the 25% average found is strong trending stocks.
Trade Setup
| Buy Target $2.35 | Sell Target 1 $3.28 |
| Trailing Stop 20% | Sell Target 2 $3.93 |
